Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

National Parkinson Foundation Expands Expert Care Network in Italy

MIAMI — The National Parkinson Foundation (NPF), a division of the Parkinson’s Foundation, announced today a new partnership with the Fresco Institute Italia to improve the quality of Parkinson’s care in Italy. The NPF Center of Excellence global network embodies the world’s leading Parkinson’s specialists focused on changing the course of Parkinson’s disease (PD). 

“The NPF Center of Excellence program is more than just a designation, it represents a philosophy of care that focuses on achieving the best we can for patients today while working to improve care for tomorrow,” said Peter Schmidt, NPF’s Senior Vice President and Chief Mission Officer.  “Working with the Fresco Institute Italia, we hope to bring this philosophy of the best care for people with Parkinson’s today to the centers guiding care in Italy.”

NPF Centers of Excellence are designated after a rigorous application and peer-review process. They collaborate on a program of continuous improvement through the Parkinson’s Outcomes Project, the largest clinical study of Parkinson’s ever conducted. This network of over 40 academic medical centers link cutting-edge research to exemplar patient-focused clinical care.  By linking research and care, the Centers of Excellence network is both a proving ground for new therapies and creating the evidence that guides the care that today’s patients receive. The network reflects NPF’s ongoing commitment to promoting greater access to expert care.

Working together, NPF and Fresco Network leadership will develop and launch programs to improve patient outcomes in Italy that builds upon the unique insight and expertise of Parkinson’s experts in Italy together with leading clinicians from around the world.

“Bringing together our great teams offers us the opportunity to share our visions in developing a comprehensive plan to improve care in Italy, and also to share our unique insight with the world-wide NPF network,” said Paolo Fresco, Founder of the Fresco Institute Italia.

NPF’s Center of Excellence network features world-renowned Parkinson’s specialists focused on reaching across patient and professional communities to change the course of Parkinson’s disease. The network serves more than 100,000 individuals diagnosed with Parkinson’s. In order to participate in the competitive designation process, centers must first meet strict criteria for research, comprehensive care, patient outreach services and professional education.  The NPF Center of Excellence network is widely credited with developing and promoting the modern Parkinson’s team model of care and ensuring patients the highest standards of care.

NPF brings all Centers of Excellence together annually to provide updates on care activities and research initiatives. Each NPF Center of Excellence must re-certify every five years in order to ensure that they maintain high standards of care. This process includes a review of achievements as well as a team-based peer evaluation including an on-site assessment.

About Parkinson's Disease (PD)

Parkinson's disease is a progressive neurological disorder that affects nearly one million people in the US and over 10 million worldwide.  Parkinson's is the second most common neurodegenerative disease after Alzheimer's and is the 14th leading cause of death in the US.  It is associated with a loss of motor control (e.g., shaking or tremor at rest and lack of facial expression) as well as non-motor symptoms (e.g., depression A mood disorder whose symptoms can include a persistent sad or empty mood, feelings of hopelessness or pessimism, irritability and loss of interest or pleasure in previously enjoyable activities. and anxiety A feeling of nervousness, worried thoughts and physical distress.).  Although promising research is being conducted, there is currently no cure for Parkinson's disease.

About the Fresco Institute Italia

The Fresco Institute Italia was created in 2015 to coordinate the activities of Italian centers dedicated to research and treatment of movement disorders with the activities of the Fresco Institute at NYU Langone Medical Center. Its main aim is to build a network of excellence in Italy, creating highly qualified centers that meet the criteria established by the National Parkinson Foundation. This objective will be achieved through promotion of joint research projects, exchanges, transfer of scientific information and new clinical treatments, training opportunities for young neurologists and scientists who want to specialize in the field of Parkinson and movement disorders. The synergies and the collaborations that distinguish the Fresco Institute Italia were created thanks to the vision, passion and support of Paolo and Marlene Fresco. For information about the Fresco Institute Italia, visit www.frescoinstituteitalia.it.

Wednesday, November 2, 2016
New Study Shows 1.2 Million People in the United States Estimated to be Living with Parkinson’s Disease by 2030
Tuesday, July 10, 2018

Parkinson’s Foundation Reveals Most Comprehensive Estimate of
Parkinson’s Prevalence in North America since the 1970’s

Parkinson’s Foundation Elects Howard D. Morgan Chairman of the Board
Tuesday, June 26, 2018

MIAMI & NEW YORK — June 26, 2018 — The Parkinson’s Foundation today announced the election of Howard D. Morgan as chairman of its board of directors. Mr. Morgan, who previously served as the Vice Chair of the nonprofit organization’s board, is a Partner and the Senior Managing Director of Argand Partners in New York.

Parkinson’s Foundation Announces Five New Members of its People with Parkinson’s Advisory Council
Wednesday, June 13, 2018

NEW YORK & MIAMI — June 13, 2018 — The Parkinson’s Foundation today announced five new members of its People with Parkinson’s Advisory Council.

The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.